Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous congestion and kidney dysfunction. Relief of the congestion has demonstrated to improve renal functions in decompensated heart failure. The current trial was set up to investigate the changes of renal venous impedance and renal arteriolar resistivity indices with diuretic therapy, in patients with congestive renal failure. The investigators asked whether measurement of renal venous impedance index or renal arteriolar resistivity index can guide the practice of diuretic therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiorenal Syndrome Cardio-Renal Syndrome Cardiovascular Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Heart Diseases Heart Failure Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ankara University School Of Medicine, Department of Cardiology

Ankara, 06230, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Decompensated heart failure
Elevated serum creatinine levels on admission

Exclusion criteria

Atrial fibrillation
Obstructive uropathy
Patients with ascites
Patients who exposed the potential nephrotoxic drugs in the previous week (metformin, antibiotics, chemotherapeutics, iodinated contrast agents and non-steroidal anti-inflammatory agents)
Patients who needed positive inotropic agents

Treatment and study plan

intravenous furosemide

Drug

Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion

Other names: Lasix

Primary outcomes

Alterations in the renal arterial resistivity index

Time frame: during hospitalization, an expected average of 4 weeks.

Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.

Secondary outcomes

Alterations in the renal venous impedance index

Time frame: during hospitalization, an expected average of 4 weeks.

Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.

Sponsors and collaborators

Lead sponsor

Ankara University

Other

Registry information

Important dates

Study start: 2013
Primary completion: 2015
Study completion: 2015
First posted: Feb 26, 2015
Registry last updated: Jun 23, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed